3x weekly Copaxone dosing receives pelminary positive......

[MSUK]

Thrice-weekly Copaxone dosing receives pelminary positive outcome in Europe

Teva Pharmaceutical Industries Ltd. announced that its thrice-weekly Copaxone® (glatiramer acetate) 40mg/ml treatment for relapsing-remitting multiple sclerosis (RRMS) has received positive results in a decentralized procedure. The favourable outcome proceeds a Positive Assessment Report from the United Kingdom, the Reference Member State’s Medicines and Healthcare Products Regulatory Agency (MHRA), and all Concerned Member States (CMS) in Europe that had participated in the procedure. The company is anticipating the granting of national marketing authorizations for Copaxone® very soon...... Read More - http://www.ms-uk.org/copaxone